Literature DB >> 15163662

Deacetylase inhibitors and the viral transactivator TaxBLV synergistically activate bovine leukemia virus gene expression via a cAMP-responsive element- and cAMP-responsive element-binding protein-dependent mechanism.

Thi Liên-Anh Nguyên1, Claire Calomme, Gaëlle Wijmeersch, Séverine Nizet, Emmanuelle Veithen, Daniel Portetelle, Yvan de Launoit, Arsène Burny, Carine Van Lint.   

Abstract

Efficient bovine leukemia virus (BLV) transcription requires the virus-encoded transactivator Tax(BLV), which acts through three Tax(BLV)-responsive elements located in the 5' long terminal repeat. It has been proposed that the binding of the CRE-binding protein (CREB) and the activating transcription factor (ATF) to the three imperfect cAMP-responsive elements (CREs) located in each Tax(BLV)-responsive element mediates Tax(BLV) transactivation. Here we demonstrated that deacetylase inhibitors (HDACis) synergistically enhanced the transcriptional activation of the BLV promoter by Tax(BLV) in a CRE-dependent manner. Tax(BLV) was acetylated in vivo at its N(alpha) terminus but not at internal lysine residues. Rather, HDACi potentiation of Tax(BLV) transactivation was mediated by an HDACi indirect action that requires new protein synthesis. Mechanistically, using a dominant-negative form of CREB, we showed that Tax(BLV) and HDACi synergistically activated BLV gene expression via a CREB-dependent mechanism. Moreover, electrophoretic mobility shift assay and Western blot experiments revealed that HDACi increased the in vitro DNA binding activity of CREB/ATF but did not alter CREB/ATF intranuclear presence. Remarkably, chromatin immunoprecipitation assays demonstrated that HDACi treatment increased the level of CREB bound to the BLV promoter in vivo. Our results together suggest that an increase in CREB/ATF occupancy of the viral CREs in response to HDACi potentiates Tax(BLV) transactivation of the BLV promoter.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163662     DOI: 10.1074/jbc.M404081200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein/CRE modulator/activation transcription factor binding.

Authors:  Valérie Pierard; Allan Guiguen; Laurence Colin; Gaëlle Wijmeersch; Caroline Vanhulle; Benoît Van Driessche; Ann Dekoninck; Jana Blazkova; Christelle Cardona; Makram Merimi; Valérie Vierendeel; Claire Calomme; Thi Liên-Anh Nguyên; Michèle Nuttinck; Jean-Claude Twizere; Richard Kettmann; Daniel Portetelle; Arsène Burny; Ivan Hirsch; Olivier Rohr; Carine Van Lint
Journal:  J Biol Chem       Date:  2010-04-22       Impact factor: 5.157

2.  Suppression of viral gene expression in bovine leukemia virus-associated B-cell malignancy: interplay of epigenetic modifications leading to chromatin with a repressive histone code.

Authors:  Makram Merimi; Pavel Klener; Maud Szynal; Yvette Cleuter; Pierre Kerkhofs; Arsène Burny; Philippe Martiat; Anne Van den Broeke
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

3.  Identification of bovine leukemia virus tax function associated with host cell transcription, signaling, stress response and immune response pathway by microarray-based gene expression analysis.

Authors:  Mariluz Arainga; Eri Takeda; Yoko Aida
Journal:  BMC Genomics       Date:  2012-03-28       Impact factor: 3.969

Review 4.  Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.

Authors:  Sabrina M Rodríguez; Arnaud Florins; Nicolas Gillet; Alix de Brogniez; María Teresa Sánchez-Alcaraz; Mathieu Boxus; Fanny Boulanger; Gerónimo Gutiérrez; Karina Trono; Irene Alvarez; Lucas Vagnoni; Luc Willems
Journal:  Viruses       Date:  2011-07-19       Impact factor: 5.048

5.  Chromatin disruption in the promoter of bovine leukemia virus during transcriptional activation.

Authors:  Laurence Colin; Ann Dekoninck; Michal Reichert; Miriam Calao; Makram Merimi; Anne Van den Broeke; Valérie Vierendeel; Yvette Cleuter; Arsène Burny; Olivier Rohr; Carine Van Lint
Journal:  Nucleic Acids Res       Date:  2011-09-02       Impact factor: 16.971

6.  Role of the cellular factor CTCF in the regulation of bovine leukemia virus latency and three-dimensional chromatin organization.

Authors:  Maxime Bellefroid; Anthony Rodari; Mathilde Galais; Peter H L Krijger; Sjoerd J D Tjalsma; Lorena Nestola; Estelle Plant; Erica S M Vos; Sara Cristinelli; Benoit Van Driessche; Caroline Vanhulle; Amina Ait-Ammar; Arsène Burny; Angela Ciuffi; Wouter de Laat; Carine Van Lint
Journal:  Nucleic Acids Res       Date:  2022-04-08       Impact factor: 16.971

7.  Animal models on HTLV-1 and related viruses: what did we learn?

Authors:  Hiba El Hajj; Rihab Nasr; Youmna Kfoury; Zeina Dassouki; Roudaina Nasser; Ghada Kchour; Olivier Hermine; Hugues de Thé; Ali Bazarbachi
Journal:  Front Microbiol       Date:  2012-09-21       Impact factor: 5.640

Review 8.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

9.  Characterization of new RNA polymerase III and RNA polymerase II transcriptional promoters in the Bovine Leukemia Virus genome.

Authors:  Benoit Van Driessche; Anthony Rodari; Nadège Delacourt; Sylvain Fauquenoy; Caroline Vanhulle; Arsène Burny; Olivier Rohr; Carine Van Lint
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

Review 10.  Regulation of Expression and Latency in BLV and HTLV.

Authors:  Aneta Pluta; Juan P Jaworski; Renée N Douville
Journal:  Viruses       Date:  2020-09-25       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.